Preliminary results from a phase 1 trial in patients with PD-1 or PD-L1 refractory cHL demonstrated favorable safety profile and encouraging clinical activity, though specific response rates and detailed safety data are pending full publication [115]. Here, CD274 is linked to classic Hodgkin lymphoma.